HSA
ABMD

HBK Sorce Advisory’s Abiomed Inc ABMD Stock Holding History

HBK Sorce Advisory’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,568
Closed -$385K – 816
2022
Q3 		$385K Buy
+1,568
New +$423K 0.03% 314
2019
Q2 		– Sell
-813
Closed -$232K – 455
2019
Q1 		$232K Sell
813
-46
-5% -$15.3K 0.02% 381
2018
Q4 		$279K Buy
859
+189
+28% +$65.7K 0.03% 308
2018
Q3 		$301K Buy
+670
New +$264K 0.03% 297

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

HBK Sorce Advisory's ABMD Position: Q4 2022 in Review

HBK Sorce Advisory sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 1,568 shares — an estimated $385K sold.

HBK Sorce Advisory first reported a position in ABMD in Q3 2018 and held it in 4 quarters. The position peaked at $385K in Q3 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • HBK Sorce Advisory reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • HBK Sorce Advisory sold 1,568 Abiomed Inc shares in Q4 2022, an estimated $385K.
  • HBK Sorce Advisory first reported a position in Abiomed Inc in Q3 2018 and held it in 4 quarters.
  • HBK Sorce Advisory's Abiomed Inc position peaked at $385K in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on HBK Sorce Advisory's 13F filing for Q4 2022, filed 9 Feb 2023.